Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

[1]  M. Mintun,et al.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.

[2]  F. Curtin,et al.  Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study , 2016, mAbs.

[3]  Robert A. Dean,et al.  Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients , 2016, Alzheimer's & Dementia.

[4]  Mike P. Wattjes,et al.  Remyelination therapy goes to trial for multiple sclerosis , 2014, Neurology: Neuroimmunology & Neuroinflammation.

[5]  R. Bateman,et al.  CNS Amyloid-β, Soluble APP-α and -β Kinetics during BACE Inhibition , 2014, The Journal of Neuroscience.

[6]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[7]  John Hardy,et al.  Antiamyloid therapy for Alzheimer's disease--are we on the right road? , 2014, The New England journal of medicine.

[8]  E. Siemers,et al.  Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease , 2012, Alzheimer's & Dementia.

[9]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[10]  D. Holtzman,et al.  Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease , 2002, Science.

[11]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[12]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[13]  H. Vanderstichele,et al.  Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. , 2013, Journal of Alzheimer's disease : JAD.